Vinay Prasad - Search Results

Year	Number of Results
2005	2
2006	2
2007	3
2008	4
2009	7
2010	8
2011	13
2012	13
2013	34
2014	37
2015	34
2016	34
2017	33
2018	45
2019	36
2020	40
2021	63
2022	57

1

Precision oncology: origins, optimism, and potential.

Prasad V, Fojo T, Brada M. Prasad V, et al. Lancet Oncol. 2016 Feb;17(2):e81-e86. doi: 10.1016/S1470-2045(15)00620-8. Lancet Oncol. 2016. PMID: 26868357 Review.

2

Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public.

Prasad VK. Prasad VK. Oncology (Williston Park). 2016 Feb;30(2):120-1. Oncology (Williston Park). 2016. PMID: 26888789 Free article. No abstract available.

3

Examining the Use of Real-World Evidence in the Regulatory Process.

Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, Yu KH. Beaulieu-Jones BK, et al. Among authors: prasad v. Clin Pharmacol Ther. 2020 Apr;107(4):843-852. doi: 10.1002/cpt.1658. Epub 2019 Nov 14. Clin Pharmacol Ther. 2020. PMID: 31562770 Free PMC article. Review.

4

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.

Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM. Del Paggio JC, et al. Among authors: prasad v. JAMA Oncol. 2021 May 1;7(5):728-734. doi: 10.1001/jamaoncol.2021.0379. JAMA Oncol. 2021. PMID: 33764385 Free PMC article. Clinical Trial.

5

The Reply.

Mandrola J, Cifu A, Prasad V, Foy A. Mandrola J, et al. Among authors: prasad v. Am J Med. 2020 May;133(5):e202. doi: 10.1016/j.amjmed.2019.12.015. Am J Med. 2020. PMID: 32450948 No abstract available.

6

Essere un medico conservativo.

Mandrola J, Cifu A, Prasad V, Foy A. Mandrola J, et al. Among authors: prasad v. Recenti Prog Med. 2019 Apr;110(4):156-158. doi: 10.1701/3154.31340. Recenti Prog Med. 2019. PMID: 31066360 Italian. No abstract available.

7

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

Marquart J, Chen EY, Prasad V. Marquart J, et al. Among authors: prasad v. JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660. JAMA Oncol. 2018. PMID: 29710180 Free PMC article.

8

The Reply.

Mandrola J, Cifu A, Prasad V, Foy A. Mandrola J, et al. Among authors: prasad v. Am J Med. 2019 Sep;132(9):e719. doi: 10.1016/j.amjmed.2019.04.024. Am J Med. 2019. PMID: 31606062 No abstract available.

9

Response.

Rho J, Ho N, Prasad V. Rho J, et al. Among authors: prasad v. Chest. 2015 Jul;148(1):e31-e32. doi: 10.1378/chest.15-0837. Chest. 2015. PMID: 26149564 Free PMC article. No abstract available.

10

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Haslam A, Prasad V. Haslam A, et al. Among authors: prasad v. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. JAMA Netw Open. 2019. PMID: 31050774 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results